Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
An efficient system to generate truncated human angiotensin converting enzyme 2 (hACE2) capable of binding RBD and spike protein of SARS-CoV2

Xiangzheng Gao, Keying Liang, Shengsheng Mei, Shanshan Peng, Eu Gene Vong, Jinbiao Zhan *

Department of Biochemistry, Cancer Institute of the Second Affiliated Hospital (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), School of Medicine, Zhejiang University, Hangzhou, 310058, China

ARTICLE INFO

Keywords:
- hACE2
- SARS-CoV2
- COVID-19
- Spike protein
- RBD

ABSTRACT

Human angiotensin converting enzyme 2 (hACE2) mediates the cell entry of both SARS-CoV and SARS-CoV2 and can be used as a drug target. The DNA encoding the truncated hACE2 (30-356aa) was cloned into pET-28a (+) and expressed in Escherichia coli Rosetta (DE3). The recombinant hACE2 (rhACE2) was purified by affinity chromatography on a Ni-NTA column and characterized with SDS-PAGE and Western blot. The binding activity of rhACE2 to Spike protein of SARS-CoV2 was evaluated in S protein-overexpressed HEK293A cells (HEK293A-SP cells) through flow cytometry. The prokaryotic expression system is able to produce approximately 75 mg protein per liter, which would be useful for infection mechanism study, and drug screening and development of SARS-CoV2.

1. Introduction

The global outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), has posed a serious threat to human health. The scientists around the world have been racing to fight with this coronavirus. Many studies have been done for elucidating the mechanism of infection. It has been found that the spike (S) protein of SARS-CoV2 binds to angiotensin converting enzyme 2 (ACE2) on cell membrane to initiate the cell entry [1].

ACE2 is a metalloprotease located on the surface of endothelial and other cells with a full length of 805 amino acids (aa) which includes an extracellular domain (18-740aa), a relatively short transmembrane region (741-761aa) and an intracellular region which exerts enzyme activity. Its extracellular domain includes N-terminal peptidase domain (PD, 18-605aa) and C-terminal collectrin-like domain (CLD, 606-740aa). ACE2 was initially identified as a homolog (or a variant) of angiotensin converting enzyme (ACE) which is a key protease that cleaves angiotensin I to form angiotensin II. Angiotensin II (Ang II) is a key regulator of renin-angiotensin system (RAS) to mediate biological functions through two G protein-coupled receptors, angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R). Subsequent studies indicated that ACE2 negatively regulates the activated RAS by degrading Ang II into heptapeptide angiotensin 1-7 [2]. Moreover, it has demonstrated that ACE2 plays a critical role in mediating the entry of SARS-CoV and SARS-CoV2 to human cells [3].

It’s been reported that SARS-CoV/SARS-CoV2 bind to the peptidase domain of ACE2 through its receptor binding domain (RBD) of spike protein and participate in the viral infection process. The strategies of blocking SARS-CoV2 Spike protein and ACE2 interaction has been widely used for anti-virus drug development. The amino acid substitution analysis indicated that K353, K31, E35, M82, N53, N90, and N322 in ACE2 would influence the binding activity of SARS-CoV/SARS-CoV2 [4]. In order to keep the functional integrity, we designed to generate the fragment (30-356aa) of hACE2 for further study. In this study, we have demonstrated that recombinant hACE2 (30-356aa) can be effectively expressed in E. coli Rosetta (DE3). The functional analysis indicated that hACE2 (30-356aa) can bind to specific antibodies and S protein of SARS-CoV2. The recombinant protein would provide a useful tool for SARS-CoV2 infection study, anti-viral drug screening and development.

2. Materials and methods

2.1. Bacteria strains and vectors

Escherichia coli Rosetta (DE3) strain was purchased from Novagen and used for cloning and expression. Plasmids pcDNA3.1-ACE2-Flag and
pcDNA3.1-Spike-Myc were purchased from Beyotime biotechnology (Shanghai, China). Of which, pcDNA3.1-hACE2-Flag was used as a template to obtain hACE2 gene through polymerase chain reaction (PCR) and pcDNA3.1-Spike-Myc was used to construct the SARS-CoV2 S protein-overexpressed HEK293A (HEK293A-SP) cells. The plasmid pcDNA3.1 was obtained from Dr. Sun Qiming’s Lab, Dept of Biochemistry, School of Medicine, Zhejiang University. The expression plasmid pET-28a (+)/RBD was constructed previously in our lab. The hACE2 gene was inserted to pET-28a (+) vector with a C-terminal His tag (6 × His).

2.2. Reagents and antibodies

DNA gel extraction kits (Omega Bio-tek, USA), AxyPrep plasmid miniprep kit (Axygen Scientific Inc, USA) were used for DNA fragments purification and plasmid extraction according to the manufacturer’s instructions. The BCA protein quantification kit and T4 DNA ligase were from Vazyme Biotech (Nanjing, China). The following reagents were purchased from Sangon Biotech (Shanghai, China): urea, imidazole, Ni-NTA sephrose resin, dialysis membrane (cutoff MW, 14 KD), polyethylene glycol-20000 (PEG20000), 50 × TAE buffer, two-color pre-stained protein marker. The 2 × Hieff PCR Master mixture, nucleic acid gel stain (10000 × in water), and DNA marker were obtained from Yeasen Biotech (Shanghai, China). NcmECL Ultra Kit was obtained from Ncm Biotech (Suzhou, China) and used for detection of Western blot.

The mouse anti-6 × His tag monoclonal antibodies was from ProteinTech Group (USA). The rabbit polyclonal antibody against SARS-CoV2 Spike RBD was from ABclonal Technology (Wuhan, China). Antibodies against the following agents were obtained from BBI Life Sciences (Shanghai, China): rabbit anti-ACE2 polyclonal antibody, rabbit anti-Myc tag polyclonal antibody, His tag monoclonal antibodies was from Proteintech Technology, Beijing) was added into the wells of microplate and incubated at 37 °C overnight. After washing with PBST (PBS, 0.1% Triton X-100) for three times, the plate was washed with distilled water, the pellet was finally dissolved in NTA buffer containing 8 M urea and purified by affinity chromatography with a Ni-NTA sephrose column (1 × 1 cm). The bound rhACE2 was eluted with 1 × NTA buffer containing 20 mM–250 mM imidazole and 8 M urea respectively. The fractions containing rhACE2 were collected and dialyzed with urea gradient including 4, 2 and 0 M in NTA buffer, and PBS respectively. The recombinant protein was concentrated and filter sterilized. The SDS-PAGE (12%) was used to analyze the purity of the recombinant protein and the protein concentration was measured by the BCA method.

2.5. Western blot analysis

The purified rhACE2 proteins were subjected to SDS-PAGE (12%) and transferred to a solid PVDF membrane (Millipore, USA) at 100 V for 60 min. Membranes were blocked with blocking buffer (5% no-fat milk dissolved in TBST (TBS, 0.1% Tween-20) and incubated separately with mouse anti-6 × His tag monoclonal antibodies (1:1500) and rabbit anti-ACE2 polyclonal antibody (1:2000) for 1 h at room temperature. The membranes were washed with TBST for three times, then the HRP-conjugated goat anti-rabbit IgG or mouse IgG antibodies (1:10,000) was incubated with membranes for 1 h at room temperature followed by three times washing with TBST.

For detection of S protein expressed in HEK293A-SP cells, the cells were washed with ice-cold PBS and then lysed by RIPA lysis buffer (Beyotime Biotechnology) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF). An equal amount of each protein sample was subjected to SDS-PAGE separation, and then transferred onto PVDF membranes. Membranes were blocked for 30 min with the blocking buffer and followed by incubation with the primary antibody and secondary antibodies. The anti-Myc tag and anti-SARS-CoV2 Spike-RBD rabbit polyclonal antibodies (1:2000) were used as primary antibodies. The HRP-conjugated goat anti-rabbit IgG antibody (1:10,000) was used as secondary antibody. The membranes were detected and visualized by using NcmECL Ultra detection reagents under the ChemiDoc™ Touch Imaging system (Bio-Rad, USA) and analyzed by Image Lab software.

2.6. Enzyme-linked immunosorbent assay (ELISA)

First, 96-well microplate (CoStar, USA) was coated with 0.625, 1.25, 2.5, 5, 10, 20 µg/mL of rhACE2 and placed at 4 °C overnight. After washing with PBST (PBS, 0.05% Tween-20), the plate was blocked with 3% non-fat milk in PBST for 1 h at 37 °C. Recombinant SARS-CoV2 (OkayBio, Nanjing, China) (1:2000) in TBST was added to each well followed by incubation at 37 °C for 1 h. Then the plate was washed for three times with PBST, the anti-RBD rabbit polyclonal antibody was added at the dilution of 1:5000 in PBST and incubated at 37 °C for 1 h. After washing with PBST three times, HRP-conjugated goat anti-rabbit IgG antibody (1:5000) was added and incubated at 37 °C for 0.5 h. Wash with PBST for six times to remove the nonspecific binding proteins. Finally, the tetramethylbenzidine (TMB) solution (Solarbio Science Technology, Beijing) was added into the wells of microplate and incubated at 37 °C for 15–20 min, followed by adding 2 M H2SO4 to terminate this reaction. Optical density at 450 nm (OD450) was measured by Synergy HT Microplate Reader (Bio-Tek, USA). The data were analyzed by GraphPad Prism 7.0.

2.7. Cell lines, cell culture and transfection

HEK293A cell line was a kindly gift from Dr. Qiming Sun’s lab (School of Medicine, Zhejiang University). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Biological Industries, Israel) with 10% fetal bovine serum (FBS, ExCell Bio) and 1% penicillin–streptomycin (Sangon Biotech, China) in a 5% CO2 incubator at 37 °C. Transfection with plasmid DNA was performed with Hieff trans-
liposomal transfection reagent (Yeasen Biotech, China) according to the manufacturer’s instructions.

To obtain stably-expressing Spike protein, HEK293A cells were transiently transfected with plasmid pcDNA3.1-Spike-Myc harboring full-length SARS-CoV2 Spike protein. After 24 h of transfection, selection reagent G418 (700 μg/ml) was added to the cells in the fresh complete medium. After 14 days, cells were digested with 0.25% Trypsin-EDTA (NCM Biotech, China) and harvested with complete DMEM medium supplied with 700 μg/ml G418. After 7 days of incubation, single clones were seeded and picked up from 96 well-plates through gradient dilution, then each single clone was transferred to a new dish with fresh complete DMEM medium. To keep the resistant phenotype of established transfected cells, the stable cell lines were maintained in medium with 400 μg/ml G418.

2.8. Flow cytometry

Flow cytometry analysis was performed to evaluate the binding ability of rhACE2 to HEK293A cells stably expressing of SARS-CoV2-Spike protein. Briefly, 2 × 10⁵ cells were incubated with rhACE2 or hACE2 (Sangon Biotech, China) for 30 min at 2–8 °C, after three times washing with PBS containing 2% FBS, then anti-His-tag mouse monoclonal antibody was added (1:200) and incubated for 30 min at 2–8 °C, followed by three times washing mentioned above. Then Goat anti-mouse IgG-Alexa Fluor® 647 antibody (1:200) was added to incubate for 30 min in the dark at 2–8 °C. Wash the cells for three times, and resuspend cells in an appropriate volume of PBS buffer. The samples were processed by ACEA NovoCyteTM (USA) and further analyzed by FlowJo V10 software.

2.9. Statistical analysis

Statistical analysis was carried out by using GraphPadPrism7.0 statistical software. Statistical significance for OD450nm of ELISA between groups was determined by grouped three replicates, and statistical significance for mean fluorescence intensity between groups was determined by grouped two replicates value in side-by-side sub-columns analysis, and p value of less than 0.05 was considered to be statistically significant. Asterisks indicate statistical compared to negative group (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
3. Results

3.1. Construction of recombinant plasmid pET-28a (+)/hACE2

The full-length human ACE2 contains 805aa, which consists of a signal peptide (1-17aa), an extracellular domain (18-740aa), a transmembrane domain (741-761aa) and the cytoplasmic domain (762-805aa) (Fig. 1A). Of which, the DNA coding hACE2 (30-356aa) was amplified by PCR using the specific primers and the template of pcDNA3.1-hACE2-Flag vector. The entire strategy of recombinant vector construction was shown by a schematic diagram (Fig. 1B). The size of desired DNA fragment is 981bp identified by 1% agarose gel electrophoresis (Fig. 1C). The DNA fragment was digested with NcoI and XhoI and subcloned into the plasmid pET-28a (+) (Fig. 1D) to generate the recombinant expression plasmid pET-28a (+)/hACE2. The products of ligation were transformed into *Escherichia coli* Rosetta (DE3) by CaCl$_2$ method. Single clones were subjected to DNA extraction and identified through PCR reaction. The band of each PCR product examined by 1% agarose gel electrophoresis showed all test samples were positive (Fig. 1E). These positive clones were further confirmed by DNA sequencing from Sangon Biotech (Shanghai, China). Sequencing results showed that the recombinant expression vector pET-28a (+)/hACE2 was constructed successfully.

3.2. Expression and purification of the recombinant hACE2

*Escherichia coli* Rosetta (DE3) host strain is designed to enhance the expression of eukaryotic proteins that contain codons rarely possessed in *Escherichia coli*. This strain provides tRNAs for 7 rare codons (AGA, AUA, CUU, CGG, GGA, CCC, and CGG) on a compatible chloramphenicol-resistant plasmid. The tRNA genes are driven by their native promoters [5]. The correct clone was subjected to protein expression by induced with 1 mM IPTG. SDS-PAGE analysis of the induced bacteria sample showed that there was a distinct band with the molecular weight about 39 kDa compared with the un-induced one. There was a large amount of insoluble protein existed in the pellet (inclusion body) but not in the supernatant after sonication (Fig. 2A). It’s been reported that expression system of pET-28a (+) usually causes insoluble inclusion body. In order to acquire enough rhACE2 similar to natural structure with correct spatial structure which is essential for the functional activity. We used 8 M urea to dissolve and denature the inclusion bodies followed by affinity purification through Ni-NTA sefinose resin system. The results of SDS-PAGE showed that the fractions eluted with NTA buffer containing 100 mM, 150 mM, 200 mM imidazole and 8 M urea contained relatively pure recombinant proteins with high yield (Fig. 2B). The rhACE2 denatured proteins were collected and refolded by serial dialysis. Two times 1 × PBS buffer were carried to the dialysis procedure finally, then the protein was concentrated with PEG20000. Here we processed the expression system with 200 ml LB medium and finally obtained 15 mg of rhACE2. The purity of rhACE2 is approximately 90% with few undesired faint bands analyzed by SDS-PAGE at the concentration of 0.5 mg/ml (Fig. 2C). The yield of rhACE2 reached about 75 mg with 1 L of LB medium expression system, which represents an efficient way to produce recombinant hACE2.

3.3. Antigenic assay and RBD binding activity of recombinant hACE2

To identify the function of the purified recombinant hACE2, the
Fig. 3. Antigenic and binding activity analysis of recombinant hACE2 in protein level. (A) Detection of rhACE2 by Western blotting with anti-6×His Tag monoclonal antibody. (B) Detection of rhACE2 by Western blotting with rabbit anti-ACE2 polyclonal antibody. Line 1–4, rhACE2 with the concentration of 0, 0.5, 2.5, 12.5 ng/ul; line 5, 12.5 ng/ul hACE2 (purchased from Sangon Biotech) (positive control); line 6, 12.5 ng/ul BSA (negative control). (C) ELISA assay. The rhACE2 binds to SARS-CoV2 RBD protein in a concentration-dependent way. Values are mean ± SD. Experiments were performed in triplicate.

Fig. 4. Recombinant hACE2 is able to bind to the HEK293A-SP cells. (A) (B) WB analysis of the overexpressed Spike protein on HEK293A-SP cells detected with rabbit anti-Myc and rabbit anti-RBD polyclonal antibody respectively. Lane 1, cell lysate of HEK293A cell transfected with plasmid pcDNA3.1-Spike-Myc; lane 2, cell lysate of HEK293A cell transfected with empty pcDNA3.1 vector (control). (C) Binding analysis of rhACE2 to HEK293A-SP cells by flow cytometry. The mean fluorescence intensity (MFI) are mean ± SD. Experiments were performed in double. HEK293A-SP cells transfected with pcDNA3.1-Spike-Myc showed more fluorescence intensity than HEK293A, indicating rhACE2 is able to bind the S protein-overexpressed cells. The BSA and commercial hACE2 (purchased from Sangon Biotech) were used as negative control (Neg Ctrl) and positive control (Pos Ctrl) respectively.
antigenic bioactivity experiment was examined by Western blot. Two tests were carried out by using the anti-His tag and anti-ACE2 antibodies respectively. The specific bands with 39 kDa were detected with both tests were carried out by using the anti-His tag and anti-ACE2 antibodies respectively. The specific bands with 39 kDa were detected with both tests.

We attempted to study the binding activity of rhACE2 to the HEK293A-SP cells which are stably expressed S protein of SARS-CoV2. First, the HEK293A was transfected with plasmid pcDNA3.1-SARS-CoV2 Spike-Myc in order to obtain a cell line stably expressing SARS-CoV2 Spike protein. We found that there is a remarkable expression of Spike protein in the transfected HEK293A cells compared to the control group. The anti-Myc tag (Fig. 4A) and anti-RBD (Fig. 4B) antibodies were used for Western blot analysis, indicating the S protein was expressed in the HEK293A-SP cells. Moreover, we found that rhACE2 is able to bind to HEK293A-SP cells with higher affinity than commercial hACE2 protein (positive control) (Fig. 4C). Thus, data from this part of our study demonstrate that the rhACE2 expressed in E. coli is able to bind SARS-CoV2 Spike protein in the cell surface of HEK293A-SP cells, which indicates that recombinant protein possesses biological activity.

3.4. Recombinant hACE2 is able to bind the S protein expressed on the surface of HEK293A-SP cells

In this study, we have established an efficient prokaryotic expression and identification system of rhACE2. This purified rhACE2 possesses efficient antigenicity and binding ability to SARS-CoV2 RBD and S protein in HEK293A-SP cells.

5. Conclusion

In summary, we provide a high-level expression and identification system of human angiotensin converting enzyme 2 (hACE2). The rhACE2 (30-356aa) has biological activity and is able to bind both RBD and S protein of SARS-CoV2 in vitro. The rhACE2 obtained from the methods described in the study is useful for basic mechanism research, and use as a target for anti-viral drug screening and development. Our finding will contribute to generate valuable antibodies or fusion protein against SARS-CoV2.

References

[1] A.R. Bourgonje, A.E. Abdhulle, W. Timens, J.-L. Hillebrands, G.J. Navis, S.J. Gordijn, M.C. Relling, G. Dijkstra, A.A. Voors, A.D. Osterhau, P.H. van der Voort, D. J. Mulder, H. van Goor, Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19), J. Pathol. 251 (2020) 228–248.
[2] L.M. Burrell, C.J. Johnston, C. Tikellis, M.E. Cooper, ACE2, a new regulator of the renin-angiotensin system, Trends Endocrinol. Metabol. 15 (2004) 166–169.
[3] P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature 579 (2020) 270–273.
[4] J. Damas, G.M. Hughes, K.C. Kroug, C.A. Painter, N.S. Persky, M. Corbo, M. Hiller, K.P. Koopfa, A.R. Pennin, H. Zhao, D.P. Genereux, R. Swoford, K.S. Pollard, O.A. Ryder, M.T. Nweeia, K. Lindblad-Toh, E.C. Teeling, E.K. Karlsson, H.A. Lewin, Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates, Proc. Natl. Acad. Sci. U. S. A. 117 (2020) 22321–22322.
[5] G.L. Rosano, E.A. Ceccarelli, Recombinant protein expression in Escherichia coli: advances and challenges, Fronit. Microbiol. 5 (2014), 172–172.
[6] K. Kabu, Y. Imai, T. Otbo-Nakanishi, J.M. Penninger, Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters, Pharmacol. Ther. 128 (2010) 119–128.
[7] W. Li, M.J. Moore, N. Vasileva, J. Sui, S.K. Wong, M.A. Berne, M. Somasundaran, J.L. Sullivan, K. Luzariaga, T.C. Greenough, H. Choe, M. Farzan, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature 426 (2003) 450–454.
[8] K. Kabu, Y. Imai, S. Rao, H. Gao, F. Guo, B. Guan, Y. Huan, P. Yang, Y. Zhang, W. Deng, L. Bao, B. Zhang, G. Liu, Z. Wang, M. Chappell, Y. Liu, D. Zheng, A. Leblizard, T. Wada, A.S. Slupsy, D. Liu, C. Qin, C. Jiang, J.M. Penninger,
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat. Med. 11 (2005) 875–879.

[9] M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, M.A. Müller, C. Drosten, S. Pöhlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2020) 271–280, e278.

[10] C.G.K. Ziegler, S.J. Allon, S.K. Nyquist, I.M. Mbano, V.N. Miao, C.N. Tzouanas, Y. Cao, A.S. Yousif, J. Bals, B.M. Hauser, J. Feldman, C. Mux, M.H. Wadsworth, S. W. Kazer, T.K. Hughes, B. Doran, G.J. Gatter, M. Vukovic, F. Taliaferro, B.E. Mead, Z. Guo, J.P. Wang, D. Gean, M. Plaisant, M. Ansari, I. Angelidis, H. Adler, J.M. S. Sucre, C.J. Taylor, B. Lin, A. Waghray, V. Mitsialis, D.P. Dwyer, K.M. Buchheit, J. A. Boyce, N.A. Barrett, T.M. Laidlaw, S.L. Carroll, L. Colonna, V. Tkachev, C. W. Peterson, A. Yu, H.B. Zheng, H.P. Gideon, C.G. Winchell, F.L. Lin, C.D. Bingle, S. B. Snapper, J.A. Krohpski, F.J. Theria, H.B. Schiller, L.E. Zaragosi, P. Barby, A. Leslie, H.-P. Kiess, J.L. Flynn, S.M. Fortune, B. Berger, R.W. Finberg, L.S. Kean, M. Garber, A.G. Schmidt, D. Lingwood, A.K. Shalek, J. Ordovala-Montanes, N. Banovich, P. Barby, A. Brahma, T. Desai, T.E. Duong, O. Eckelberg, C. Falk, M. Farzan, I. Glass, M. Haniffa, P. Horvath, D. Hung, N. Kaminiski, M. Kramnow, J. A. Kroopki, M. Kuhuemund, R. Lafaitis, H. Lee, S. Leroy, S. Linnarson, J. Lundeberg, K. Meyer, A. Misharin, M. Nawijn, M.Z. Nikolic, J. Ordovala-Montanes, D. Pe’er, J. Powell, S. Quake, J. Rajagopal, P.R. Tata, E.L. Rawlins, A. Regev, P.A. Reyfman, M. Rojas, O. Rosen, K. Saeb-Parsy, C. Samakovlis, H. Schiller, J.L. Schultz, M.A. Selbod, A.K. Shalek, D. Shepherd, J. Spence, A. Spira, X. Sun, S. Teichmann, F. Theis, A. Tranek, M. van den Berge, M. von Papen, J. Whitnet, R. Xavier, Y. Xu, L.-E. Zaragosi, K. Zhang, SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues, Cell 181 (2020) 1016–1035, e1019.

[11] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xie, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506.

[12] A. Wajnberg, F. Amanat, A. Firpo, D.R. Altman, M.J. Bailey, M. Mansour, M. McMahon, P. Meade, D.R. Mendo, K. Mueller, D. Stadlbauer, K. Stone, S. Strohsmeier, V. Simon, J. Aberg, D.L. Reich, F. Krammer, C. Gordon-Carle, Robust neutralizing antibodies to SARS-CoV-2 infection persist for months, Science 370 (2020) 1227.

[13] A. Zoufaly, M. Poglitsch, J.H. Aberle, W. Hoeppler, T. Seitz, M. Traugott, A. Grieb, E. Pawelka, H. Laferl, C. Wenisch, S. Neuhold, D. Haider, K. Stiarny, A. Berghal, E. Puchhammer-Stoeckl, A. Mirazimi, N. Montserrat, H. Zhang, A.S. Slatsky, J. M. Penninger, Human recombinant soluble ACE2 in severe COVID-19, The Lancet Respiratory Medicine 8 (2020) 1154–1158.